These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15071363)

  • 1. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers.
    Zapater P; Novalbos J; Gallego-Sandín S; Hernández FT; Abad-Santos F
    J Cardiovasc Pharmacol; 2004 May; 43(5):737-44. PubMed ID: 15071363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W; Muscará MN; Martins AR; Moreno H; Mendes GB; de Nucci G
    Eur J Clin Pharmacol; 1996; 50(5):399-405. PubMed ID: 8839663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
    Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
    J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis.
    Matalka K; Arafat T; Hamad M; Jehanli A
    Fundam Clin Pharmacol; 2002 Jun; 16(3):237-44. PubMed ID: 12165071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
    Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
    Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro.
    Weisser K; Schloos J
    Biochem Pharmacol; 1991 Oct; 42(9):1729-37. PubMed ID: 1656995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays.
    Arafat T; Awad R; Hamad M; Azzam R; Al-Nasan A; Jehanli A; Matalka K
    J Clin Pharm Ther; 2005 Aug; 30(4):319-28. PubMed ID: 15985045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of zinc depletion on angiotensin I-converting enzyme in arterial walls and plasma of the rat.
    Dahlheim H; White CL; Rothemund J; von Lutterotti N; Jacob IC; Rosenthal J
    Miner Electrolyte Metab; 1989; 15(3):125-9. PubMed ID: 2542744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
    Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
    Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compared properties of trandolapril, enalapril, and their diacid metabolites.
    Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
    Edeki T; Johnston A; Li Kam Wa E; Turner P
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man.
    Cziraki A; Horvath I; Rubin JW; Theodorakis M; Catravas JD
    Gen Pharmacol; 2000 Oct; 35(4):213-8. PubMed ID: 11827728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans.
    Ueda S; Meredith PA; Morton JJ; Connell JM; Elliott HL
    Circulation; 1998 Nov; 98(20):2148-53. PubMed ID: 9815869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphonic acid group, on the activity of angiotensin converting enzyme from human kidney.
    Hiwada K; Inoue Y; Kokubu T
    Gen Pharmacol; 1990; 21(4):555-8. PubMed ID: 2165961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition.
    Nishiyama A; Seth DM; Navar LG
    J Am Soc Nephrol; 2002 Sep; 13(9):2207-12. PubMed ID: 12191964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
    Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B
    Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
    Petrie MC; Padmanabhan N; McDonald JE; Hillier C; Connell JM; McMurray JJ
    J Am Coll Cardiol; 2001 Mar; 37(4):1056-61. PubMed ID: 11263608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic inhibition of human angiotensin I-converting enzyme by enalaprilat.
    Lee EJ
    Eur J Clin Pharmacol; 1995; 49(3):173-5. PubMed ID: 8665992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum angiotensin converting enzyme activity and response to angiotensin I in horses.
    Tillman LG; Moore JN
    Equine Vet J Suppl; 1989 Jun; (7):80-3. PubMed ID: 9118114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.